Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 8/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | CD38 | P28907 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16741227 | 0.78 | HPGD (0.43) | SMYD3NPC1RAB9ASMN1; SMN2HSD11B1 | |
| SCHEMBL16741113 | 0.77 | HSD11B1 (0.40) | SMYD3NPC1RAB9ACD38HSD11B1 | |
| SCHEMBL16741143 | 0.74 | PARP1 (0.56) | SMYD3CD38HSD11B1PRKAA2BRD4 | |
| SCHEMBL25912472 | 0.74 | DPP4 (0.47) | SMYD3NPC1RAB9ASMN1; SMN2CD38 | |
| SCHEMBL2990214 | 0.69 | CHRNB2 (0.43) | SMYD3HSD11B1ALDH1A1PRKAA2 | |
| SCHEMBL16741232 | 0.68 | SMYD3 (0.46) | SMYD3NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25698486 | 0.68 | CHRM4 (0.49) | SMYD3NPC1RAB9ASMN1; SMN2CD38 | |
| SCHEMBL23505994 | 0.68 | SMYD3 (0.48) | SMYD3NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9908373 | 0.68 | SMYD3 (0.56) | SMYD3NPC1RAB9ASMN1; SMN2PRKAA2 | |
| SCHEMBL23505914 | 0.68 | SMYD3 (0.48) | SMYD3NPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189839-B2 | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase | ACTELION PHARMACEUTICALS LTD (CH) | 2019-01-29 | — | — | US | claimed |
| EP-3071578-B1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-01-10 | — | — | EP | claimed |
| US-9765092-B2 | Tricyclic piperidine compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-19 | — | — | US | claimed |
| EP-3071567-B1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-06 | — | — | EP | claimed |
| US-20160289232-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | ACTELION PHARMACEUTICALS LTD (CH) | 2016-10-06 | — | — | US | claimed |
| EP-3071578-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd (CH) | 2016-09-28 | — | — | EP | claimed |
| EP-3071567-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | Actelion Pharmaceuticals Ltd (CH) | 2016-09-28 | — | — | EP | claimed |
| US-20160272655-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-09-22 | — | — | US | claimed |
| WO-2015075025-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | ACTELION PHARMACEUTICALS LTD (CH) | 2015-05-28 | — | — | WO | claimed |
| WO-2015075023-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-05-28 | — | — | WO | claimed |
| US-10189839-B2 | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase | ACTELION PHARMACEUTICALS LTD (CH) | 2019-01-29 | — | — | US | disclosed |
| EP-3071578-B1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2018-01-10 | — | — | EP | disclosed |
| US-9765092-B2 | Tricyclic piperidine compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-19 | — | — | US | disclosed |
| EP-3071567-B1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | ACTELION PHARMACEUTICALS LTD (CH) | 2017-09-06 | — | — | EP | disclosed |
| US-20160289232-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | ACTELION PHARMACEUTICALS LTD (CH) | 2016-10-06 | — | — | US | disclosed |
| EP-3071567-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | Actelion Pharmaceuticals Ltd (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-3071578-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd (CH) | 2016-09-28 | — | — | EP | disclosed |
| US-20160272655-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-09-22 | — | — | US | disclosed |
| WO-2015075023-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-05-28 | — | — | WO | disclosed |
| WO-2015075025-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | ACTELION PHARMACEUTICALS LTD (CH) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189839-B2 | Tricyclic imidazole compounds as inhibitors of tryptophan hydroxylase | TPH1, TPH2, MAOB | SMYD3 1907/4885NPC1 2247/4885RAB9A 2670/4885 |
| US-20160272655-A1 | TRICYCLIC PIPERIDINE COMPOUNDS | TPH1, HTR1B, HTR1A | SMYD3 2161/4885NPC1 1088/4885RAB9A 1354/4885 |
| US-20160289232-A1 | TRICYCLIC IMIDAZOLE COMPOUNDS AS INHIBITORS OF TRYPTOPHAN HYDROXYLASE | TPH1, TPH2, MAOB | SMYD3 1907/4885NPC1 2247/4885RAB9A 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.